Proposed Data Collections Submitted for Public Comment and Recommendations, 32613-32614 [E9-16141]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 129 / Wednesday, July 8, 2009 / Notices
Sandra L. Kusumoto,
Director, Bureau of Certification and
Licensing.
[FR Doc. E9–16104 Filed 7–7–09; 8:45 am]
FOR FURTHER INFORMATION CONTACT: Mr.
William Clark, Procurement Analyst,
Contract Policy Division, GSA, (202)
219–1813.
BILLING CODE P
A. Purpose
DEPARTMENT OF DEFENSE
GENERAL SERVICES
ADMINISTRATION
NATIONAL AERONAUTICS AND
SPACE ADMINISTRATION
[OMB Control No. 9000–0107]
Federal Acquisition Regulation;
Information Collection; Notice of
Radioactive Materials
mstockstill on DSKH9S0YB1PROD with NOTICES
AGENCIES: Department of Defense (DOD),
General Services Administration (GSA),
and National Aeronautics and Space
Administration (NASA).
ACTION: Notice of request for comments
regarding the reinstatement of a
previously existing OMB clearance.
SUMMARY: Under the provisions of the
Paperwork Reduction Act of 1995 (44
U.S.C. Chapter 35), the Federal
Acquisition Regulation (FAR),
Regulatory Secretariat will be
submitting to the Office of Management
and Budget (OMB) a request to review
and approve an extension of a currently
approved information collection
requirement concerning Notice of
Radioactive Materials.
Public comments are particularly
invited on: Whether this collection of
information is necessary; whether it will
have practical utility; whether our
estimate of the public burden of this
collection of information is accurate,
and based on valid assumptions and
methodology; ways to enhance the
quality, utility, and clarity of the
information to be collected; and ways in
which we can minimize the burden of
the collection of information on those
who are to respond, through the use of
appropriate technological collection
techniques or other forms of information
technology.
DATES: Submit comments on or before
September 8, 2009.
ADDRESSES: Submit comments regarding
this burden estimate or any other aspect
of this collection of information,
including suggestions for reducing this
burden, to: General Services
Administration, Regulatory Secretariat
(VPR), 1800 F Street, NW., Room 4041,
Washington, DC 20405. Please cite OMB
Control No. 9000–0107, Notice of
Radioactive Materials, in all
correspondence.
VerDate Nov<24>2008
17:23 Jul 07, 2009
Jkt 217001
The clause at FAR 52.223–7, Notice of
Radioactive Materials, requires
contractors to notify the Government
prior to delivery of items containing
radioactive materials. The purpose of
the notification is to alert receiving
activities that appropriate safeguards
may need to be instituted. The notice
shall specify the part or parts of the
items which contain radioactive
materials, a description of the materials,
the name and activity of the isotope, the
manufacturer of the materials, and any
other information known to the
contractor which will put users of the
items on notice as to the hazards
involved.
B. Annual Reporting Burden
Respondents: 500.
Responses per Respondent: 5.
Annual Responses: 2,500.
Hours per Response: 1.
Total Burden Hours: 2,500.
Obtaining Copies of Proposals:
Requesters may obtain a copy of the
information collection documents from
the General Services Administration,
Regulatory Secretariat (VPR), 1800 F
Street, NW., Room 4041, Washington,
DC 20405, telephone (202) 501–4755.
Please cite OMB Control No. 9000–0107,
Notice of Radioactive Materials, in all
correspondence.
Dated: June 23, 2009.
Al Matera,
Director, Office of Acquisition Policy.
[FR Doc. E9–15978 Filed 7–7–09; 8:45 am]
BILLING CODE 6820–EP–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–09–0788]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
32613
the data collection plans and
instruments, call 404–639–5960 and
send comments to Maryam I. Daneshvar,
CDC Assistant Reports Clearance
Officer, 1600 Clifton Road, MS–D74,
Atlanta, GA 30333 or send an e-mail to
omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
Registry of Unexplained Fatiguing
Illnesses and Chronic Fatigue Syndrome
(CFS) in and around Bibb County,
Georgia, (OMB No. 0920–0788)—
Extension—National Center for
Zoonotic, Vector-borne and Enteric
Diseases (NCZVED), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
CDC has been conducting a providerbased Registry for unexplained fatiguing
illnesses and CFS for almost one year.
During this time, the objective of the
registry was to identify persons with
unexplained fatiguing illnesses,
including CFS, who access the
healthcare system and endorse referral
criteria: Age 12 to 59 years with ≥1
month of severe fatigue plus one other
core CFS symptom and no exclusionary
conditions. Eligible patients undergo a
telephone interview to assess symptoms
and exclusionary criteria. If they meet
age and exclusionary criteria and
endorse ≥6 months of symptoms, they
are invited for a 1-day clinical
evaluation, including a physical exam,
collection of specimens (blood, urine
and saliva), and psychiatric interview to
further assess exclusionary conditions,
and answer self-administered
questionnaires to measure symptoms,
functioning and exposure to potential
risk factors. Over 800 health-care
providers of various medical and
alternative medicine specialties have
enrolled and have referred over 50
patients.
CDC plans to continue to enroll
patients in the Registry study using the
same protocol. Specific aims of the
E:\FR\FM\08JYN1.SGM
08JYN1
32614
Federal Register / Vol. 74, No. 129 / Wednesday, July 8, 2009 / Notices
registry are: (1) Continue to identify and
enroll patients with CFS and other
unexplained fatiguing illnesses who are
receiving medical and ancillary medical
care and describe their epidemiologic
and clinical characteristics; (2) assess
and monitor the health care providers’
knowledge, attitudes, and beliefs
concerning CFS; (3) and to identify
well-characterized CFS patients for
future clinical studies and intervention
trials. These specific aims require
inclusion of subjects in early stages of
CFS (i.e., ill less than one year duration)
who can be followed longitudinally to
assess changes in their CFS symptoms;
persons with longer duration of fatigue
will also be eligible.
There is no cost to respondents other
than their time.
ESTIMATE OF ANNUALIZED BURDEN TABLE
Number of
respondents
Respondent
Number of
responses per
respondent
Average
burden per
response
(hours)
Total burden
(hours)
Referring Providers ..........................................................................................
Patient consent to be contacted ......................................................................
Patient Telephone Interview ............................................................................
Patient Clinical Evaluation ...............................................................................
200
340
289
221
2
1
1
1
5/60
10/60
44/60
9
33
57
212
1,989
Total Burden .............................................................................................
........................
........................
........................
2,291
Dated: June 30, 2009.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E9–16141 Filed 7–7–09; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0664]
Vaccines and Related Biological
Products Advisory Committee; Notice
of Meeting
AGENCY:
Food and Drug Administration,
HHS.
mstockstill on DSKH9S0YB1PROD with NOTICES
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Vaccines and
Related Biological Products Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on July 23, 2009, from 8 a.m. to
approximately 4 p.m.
Location: Hilton Hotel Washington
DC North/Gaithersburg, Montgomery
Ballroom, 620 Perry Pkwy.,
Gaithersburg, MD 20877.
Contact Person: Christine Walsh or
Denise Royster, Center for Biologics
Evaluation and Research, Food and
Drug Administration, 1401 Rockville
Pike, Rockville, MD 20852, 301–827–
0314, or FDA Advisory Committee
VerDate Nov<24>2008
17:23 Jul 07, 2009
Jkt 217001
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area), code 3014512391. Please call the
Information Line for up-to-date
information on this meeting. A notice in
the Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
agency’s Web site and call the
appropriate advisory committee hot
line/phone line to learn about possible
modifications before coming to the
meeting.
Agenda: The committee will discuss
clinical trials to support use of vaccines
against the 2009 H1N1 influenza virus.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm, click on the year 2009 and
scroll down to the appropriate advisory
committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before July 16, 2009. Oral
presentations from the public will be
scheduled between approximately 1
p.m. and 2 p.m. Those desiring to make
formal oral presentations should notify
the contact person and submit a brief
statement of the general nature of the
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before July 15, 2009. Time allotted for
each presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by July 9, 2009.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Christine
Walsh or Denise Royster at least 7 days
in advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: June 29, 2009.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E9–16099 Filed 7–7–09; 8:45 am]
BILLING CODE 4160–01–S
E:\FR\FM\08JYN1.SGM
08JYN1
]]>Agencies
[Federal Register Volume 74, Number 129 (Wednesday, July 8, 2009)]
[Notices]
[Pages 32613-32614]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-16141]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-09-0788]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-639-5960
and send comments to Maryam I. Daneshvar, CDC Assistant Reports
Clearance Officer, 1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send
an e-mail to omb@cdc.gov.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology. Written comments should be received
within 60 days of this notice.
Proposed Project
Registry of Unexplained Fatiguing Illnesses and Chronic Fatigue
Syndrome (CFS) in and around Bibb County, Georgia, (OMB No. 0920-
0788)--Extension--National Center for Zoonotic, Vector-borne and
Enteric Diseases (NCZVED), Centers for Disease Control and Prevention
(CDC).
Background and Brief Description
CDC has been conducting a provider-based Registry for unexplained
fatiguing illnesses and CFS for almost one year. During this time, the
objective of the registry was to identify persons with unexplained
fatiguing illnesses, including CFS, who access the healthcare system
and endorse referral criteria: Age 12 to 59 years with [gteqt]1 month
of severe fatigue plus one other core CFS symptom and no exclusionary
conditions. Eligible patients undergo a telephone interview to assess
symptoms and exclusionary criteria. If they meet age and exclusionary
criteria and endorse [gteqt]6 months of symptoms, they are invited for
a 1-day clinical evaluation, including a physical exam, collection of
specimens (blood, urine and saliva), and psychiatric interview to
further assess exclusionary conditions, and answer self-administered
questionnaires to measure symptoms, functioning and exposure to
potential risk factors. Over 800 health-care providers of various
medical and alternative medicine specialties have enrolled and have
referred over 50 patients.
CDC plans to continue to enroll patients in the Registry study
using the same protocol. Specific aims of the
[[Page 32614]]
registry are: (1) Continue to identify and enroll patients with CFS and
other unexplained fatiguing illnesses who are receiving medical and
ancillary medical care and describe their epidemiologic and clinical
characteristics; (2) assess and monitor the health care providers'
knowledge, attitudes, and beliefs concerning CFS; (3) and to identify
well-characterized CFS patients for future clinical studies and
intervention trials. These specific aims require inclusion of subjects
in early stages of CFS (i.e., ill less than one year duration) who can
be followed longitudinally to assess changes in their CFS symptoms;
persons with longer duration of fatigue will also be eligible.
There is no cost to respondents other than their time.
Estimate of Annualized Burden Table
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per Total burden
Respondent respondents responses per response (hours)
respondent (hours)
----------------------------------------------------------------------------------------------------------------
Referring Providers............................. 200 2 5/60 33
Patient consent to be contacted................. 340 1 10/60 57
Patient Telephone Interview..................... 289 1 44/60 212
Patient Clinical Evaluation..................... 221 1 9 1,989
---------------------------------------------------------------
Total Burden................................ .............. .............. .............. 2,291
----------------------------------------------------------------------------------------------------------------
Dated: June 30, 2009.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. E9-16141 Filed 7-7-09; 8:45 am]
BILLING CODE 4163-18-P
